Wire · opportunities
Psychedelics are on the FDA's mind
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 September 2026 · Fusion42 review
The FDA is intensifying its focus on psychedelics, holding a public hearing and considering new regulatory frameworks for their therapeutic use, especially in mental health and pain management. This follows recent executive orders and priority review vouchers granted to companies developing psychedelic treatments.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
The FDA is opening the medical psychedelics market with new regulatory pathways and safety requirements. You need to prepare for emerging clinical standards and potential expedited approvals in mental health and pain treatment.
◆ Coverage
1 source · 12 Sep 2026
◆ Related on Wire
◆ Topics